Long-Term Protection Study of Shigella Vaccine in Children
Part of Infections clinical trials.
This study checks how long the altSonflex1-2-3 Shigella vaccine protects children, by looking at children who already received it in earlier studies about a year ago.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have taken part in one of the earlier vaccine studies (H06_01TP or H06_02TP) as a baby and received the Shigella vaccine or a placebo.
- Your child should be about 12 months past their last dose of the Shigella vaccine.
- Your child must be in good general health without any serious or unstable medical conditions.
- Your child cannot have a weakened immune system (from HIV, autoimmune disease, or immune-suppressing drugs).
- Your child cannot have a fever or acute illness on the day of enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a Shigella (gut infection) vaccine and additives to see how safe they are in healthy adults. If you qualify, you may help researchers understand whether the vaccine triggers any unwanted immune or stomach side effects.
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
This trial tests a new vaccine called IP-QSV to see if it is safe and creates an immune response against Shigella bacteria, a common cause of diarrhea. It is for healthy adults, adolescents, children, and infants.
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
This study tests how well a recommended treatment works for children aged 6 months to 5 years who have diarrhea caused by Shigella bacteria. It aims to find the best way to help children recover faster.
This Phase 1 study gives a carefully measured dose of Shigella sonnei to healthy adults to learn about the infection’s safety and how the body responds. It may help researchers build safer future tests or treatments, but it requires a hospital stay and many follow-up visits.
Hear when a new Diarrhoea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.